Nestlé to sell skin health business for $10B

Consumer goods giant Nestlé is in talks to sell its skin health business to private equity firm EQT and the Abu Dhabi Investment Authority for $10.1 billion, The Wall Street Journal reported.

Nestlé’s skin health portfolio includes products Cetaphil and Proactiv, as well as skin cancer treatments and skin-care products from Valeant Pharmaceuticals, and generated 2.8 billion francs in net sales in 2018, according to the WSJ.

The acquisition price is at the high end of investor estimates. EQT is a major buyout firm with $44.8 billion in assets under management. The high price tag underscores the increased influx of cash flowing into the healthcare space. The story comes after Nestlé sold its life insurance business for $1.55 billion last year.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.